BoneSupport receives FDA market authorization for antibiotic-eluting bone graft
Click Here to Manage Email Alerts
BoneSupport has announced FDA market authorization of the Cerament G bone graft for patients with osteomyelitis, according to a press release.
The Cerament G bone graft, which is protected by locally eluted antibiotics, is designed to facilitate bone healing and reduce the risk of reinfection and amputation, according to the release.
“The announcement from the FDA means that BoneSupport achieves the most important milestone in the company’s commercial history to date,” Emil Billbäck, CEO of BoneSupport, said in the release. “The benefits of Cerament G for patients and clinics, have been validated in several strong clinical trials, and have paved the way for our strong sales in Europe, where Cerament G accounts for a clear majority of our sales,” he added.
Read more about
Click Here to Manage Email Alerts